» Articles » PMID: 16969356

Preoperative Elevation of Serum C--reactive Protein is Predictive for Prognosis in Myeloma Bone Disease After Surgery

Overview
Journal Br J Cancer
Specialty Oncology
Date 2006 Sep 14
PMID 16969356
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated whether preoperative levels of serum C-reactive protein (CRP) and its correlation with tumour clinicopathological findings adds prognostic information beyond the time of diagnosis in patients with myeloma bone disease (MM) to facilitate the surgical decision-making process. Six hundred and fifty-eight myeloma patients were evaluated retrospectively for surgery. Clinicopathological variables of patients who underwent surgery (n=71) were compared between patients with preoperative CRP>or=6 mg l-1 and those with CRP<6 mg l-1. Univariate and multivariate analyses were performed to identify prognostic factors after surgery. Patients with an increase of CRP prior to surgery showed inferior survival compared to patients with normal levels. Patients with normal CRP levels at diagnosis but elevations prior to surgery do seem to have a similar unfavourable overall survival (OS) than patients with an increase both, at diagnosis and at surgery. Conversely, patients with normal CRP levels prior to surgery still have the best OS, irrespective of their basic values. Multivariate analysis revealed preoperative CRP levels above 6 mg l-1 Lactate dehydrogenase (LDH) above normal, and osteolyses in long weight bearing bones as independent predictors of survival. These findings suggest that in patients with MM serum levels of CRP increase during disease activity and might be significantly correlated with specific disease characteristics including adverse prognostic features such as osteolyses in long weight bearing bones. Thus, preoperative elevated CRP serum levels might be considered as independent predictor of prognosis and could provide additional prognostic information for the risk stratification before surgical treatment in patients with myeloma bone disease.

Citing Articles

Percutaneous vertebroplasty/kyphoplasty contributes to the improved outcome in patients with newly diagnosed multiple myeloma: A single center cohort study.

Zhang F, Liu S, Zhou X, Wang W, Jia C, Wang Q J Bone Oncol. 2024; 47:100615.

PMID: 39036812 PMC: 11259919. DOI: 10.1016/j.jbo.2024.100615.


C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.

Mouliou D Diseases. 2023; 11(4).

PMID: 37873776 PMC: 10594506. DOI: 10.3390/diseases11040132.


Is surgical indication in multiple myeloma a poor prognosis sign? SEER database analysis.

Ozturk R, Amer K, Gencoglu A, Ozturk F, Kasali K, Aytekin M Clin Transl Oncol. 2023; 26(2):524-531.

PMID: 37535183 DOI: 10.1007/s12094-023-03273-8.


Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?.

Bruserud O, Aarstad H, Anderson Tvedt T Cancers (Basel). 2020; 12(7).

PMID: 32707721 PMC: 7409204. DOI: 10.3390/cancers12071966.


Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.

Zhang L, Pan L, Xiang B, Zhu H, Wu Y, Chen M Oncotarget. 2016; 7(21):30876-91.

PMID: 27129167 PMC: 5058725. DOI: 10.18632/oncotarget.9021.


References
1.
Morgan G, Davies F . Evolving treatment strategies for myeloma. Br J Cancer. 2005; 92(2):217-21. PMC: 2361851. DOI: 10.1038/sj.bjc.6602341. View

2.
Tricot G, Barlogie B, van Rhee F . Treatment advances in multiple myeloma. Br J Haematol. 2004; 125(1):24-30. DOI: 10.1111/j.1365-2141.2004.04851.x. View

3.
Biro L, Domjan G, Falus A, Jakab L, Cseh K, Kalabay L . Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur J Clin Invest. 1998; 28(8):679-86. DOI: 10.1046/j.1365-2362.1998.00333.x. View

4.
Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M . Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol. 1998; 100(1):129-34. DOI: 10.1046/j.1365-2141.1998.00538.x. View

5.
Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R . Simple prognostic model for patients with multiple myeloma: a single-center study in Japan. Ann Hematol. 2002; 81(1):33-6. DOI: 10.1007/s00277-001-0388-5. View